The Minimally Important Difference for the Health Assessment Questionnaire in Rheumatoid Arthritis Clinical Practice Is Smaller Than in Randomized Controlled Trials

REFERENCES

1. 1.↵
   1. Fries JF,
   2. Spitz P,
   3. Kraines RG,
   4. Holman HR

   . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Tugwell P,
   2. Wells G,
   3. Strand V,
   4. et al

   . Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506–14.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Wolfe F,
   2. Michaud K,
   3. Gefeller O,
   4. Choi HK

   . Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530–42.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Sloane JA

   . Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD 2005;2:57–62.

   OpenUrlPubMed
5. 5.↵
   1. Kvien TK,
   2. Heiberg T,
   3. Hagen KB

   . Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis 2007;66 Suppl:iii40–iii41.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Norman GR,
   2. Sloane JA,
   3. Wyrwich KW

   . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Wells GA,
   2. Tugwell P,
   3. Kraag GR,
   4. Baker PR,
   5. Groh J,
   6. Redelmeier DA

   . Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 1993;20:557–60.

   OpenUrlPubMed
8. 8.↵
   1. Redelmeier DA,
   2. Lorig K

   . Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337–42.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kosinski M,
   2. Zhao SZ,
   3. Dedhiya S,
   4. Osterhaus JT,
   5. Ware JE

   . Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478–87.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Strand V,
    2. Tugwell P,
    3. Bombardier C,
    4. et al

    . Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870–8.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Strand V,
    2. Crawford B

    . Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Exp Rev Pharmacoeconomics Outcomes Res 2005;5:317–26.

    OpenUrlCrossRef
12. 12.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. et al

    . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Khanna D,
    2. Furst DE,
    3. Hays RD,
    4. et al

    . Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325–9. Epub 2006 Mar 15.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Cohen J

    . A power primer. Psychol Bull 1992;112:155–9.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Crosby RD,
    2. Kolotkin RL,
    3. Williams GR

    . Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395–407.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Wolfe F,
    2. Michaud K,
    3. Strand V

    . Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583–9.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Aletaha D,
    2. Smolen J,
    3. Ward MM

    . Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Wyrwich KW

    . Minimal important difference thresholds and the standard error of measurement: is there a connection? J Biopharm Stat 2004;14:97–110.

    OpenUrlCrossRefPubMed
19. 19.
    1. Wyrwich KW,
    2. Tierney WM,
    3. Wolinsky FD

    . Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861–73.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Wyrwich KW,
    2. Nienaber NA,
    3. Tierney WM,
    4. Wolinsky FD

    . Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469–78.

    OpenUrlCrossRefPubMed